1.Vitamin D supplementation inhibits atherosclerosis through repressing macrophage-induced inflammation via SIRT1/mTORC2 signaling.
Yuli WANG ; Qihong NI ; Yongjie YAO ; Shu LU ; Haozhe QI ; Weilun WANG ; Shuofei YANG ; Jiaquan CHEN ; Lei LYU ; Yiping ZHAO ; Meng YE ; Guanhua XUE ; Lan ZHANG ; Xiangjiang GUO ; Yinan LI
Chinese Medical Journal 2025;138(21):2841-2843
2.Butyrate-based ionic liquid for improved oral bioavailability and synergistic anti-colorectal cancer activity of glycyrol.
Ziyu WANG ; Xingyue SHI ; Yikang SHU ; Ran GAO ; Ting SUN ; Mingyue WU ; Mingxin DONG ; Weiguo WU ; Ruili MA ; Daoquan TANG ; Min YE ; Shuai JI
Journal of Pharmaceutical Analysis 2025;15(11):101359-101359
Image 1.
3.Impact of PCSK9 Inhibitor Recaticimab on Hyperlipidemia and Plasma Glucose: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study.
Ye HU ; Chen CHEN ; Xiao Hui HE ; Shu Yu ZHANG ; Xu Hong WANG
Biomedical and Environmental Sciences 2025;38(10):1246-1254
OBJECTIVE:
Recaticimab (SHR-1209) significantly reduces low-density lipoprotein cholesterol levels. However, its effect on glucose metabolism remains unclear. This study aimed to evaluate its effect on glycemic parameters in a Chinese population.
METHODS:
Recaticimab versus placebo was administered in a 5:1 ratio to 110 hyperlipidemia patients who were followed up for 24 weeks. Glycated hemoglobin (HbA1c) levels were measured at baseline every 12 weeks. Fasting plasma glucose (FPG) levels were measured at baseline at week 1, 3, 5, 8, 12, 16, 20, and 24. Repeated-measures mixed-effects models were used to determine the longitudinal association between reacticimab and FPG and HbA1c levels.
RESULTS:
Among the 81 participants with normal glucose metabolism, HbA1c levels significantly decreased ( F = 4.568, P = 0.036). In the 29 participants with abnormal glucose metabolism, a significant time effect was observed for FPG levels ( F = 2.492, P = 0.016). For participants with normal and abnormal glucose metabolism, no significant group × time interaction effects on FPG or HbA1c levels were identified.
CONCLUSION
Recaticimab showed no adverse glycemic effects in participants with normal or abnormal glucose metabolism, indicating its safety in patients with or without diabetes.
Humans
;
Male
;
Female
;
Blood Glucose/drug effects*
;
Middle Aged
;
Double-Blind Method
;
Hyperlipidemias/blood*
;
Antibodies, Monoclonal, Humanized/therapeutic use*
;
PCSK9 Inhibitors
;
Glycated Hemoglobin
;
Aged
;
Adult
;
Proprotein Convertase 9
4.Research progress of cooling therapy for heat stroke
Jin-Bao ZHAO ; Qian WANG ; Tian-Yu XIN ; Han-Ding MAO ; Ye TAO ; Bo NING ; Zhen-Zhen QIN ; Shu-Yuan LIU ; Qing SONG
Medical Journal of Chinese People's Liberation Army 2025;50(5):612-618
Heat stroke is a heat-related illness caused by an imbalance between the body's heat production and heat dissipation,which could lead to multiple organ dysfunction syndrome with a high mortality rate.Rapid and effective reduction of core body temperature is key to successful treatment.This article reviews recent progress in the treatment of heat stroke,including new understandings of organ injury mechanisms,the timing,velocity and goals of cooling treatment,evaluation and selection of traditional cooling techniques(such as cold water immersion),and scientific evaluation of new cooling technologies(such as blood purification technology and intravascular heat exchange cooling technology),aiming to promote understanding and treatment of heat stroke.
5.Analysis of the Current Status of China's Adaptation Guidelines
Ling WANG ; Yaxuan REN ; Xufei LUO ; Di ZHU ; Zhewei LI ; Ye WANG ; Bingyi WANG ; Huayu ZHANG ; Shu YANG ; Yaolong CHEN
Medical Journal of Peking Union Medical College Hospital 2024;15(1):192-201
6.Pharmacokinetics of JS026 and JS026-JS016 for single intravenous administration in healthy volunteers
Yan TIAN ; Hui-Jing YE ; Jing-Jing WANG ; Nan-Yang LI ; Juan MA ; Xi TAN ; Fan WU ; Jie WANG ; Shu-Yan YU ; Xiao-Jie WU ; Jin-Jie HE ; Jing ZHANG ; Wen-Hong ZHANG
The Chinese Journal of Clinical Pharmacology 2024;40(15):2251-2255
Objective To evaluate tolerability,safety and pharmacokinetics of JS026 and JS026-JS016 single dose intravenous infusion in healthy adults.Methods This phase 1,randomized,double-blind,placebo-controlled,dose-escalation study totally included 48 participants:32 healthy subjects were enrolled in JS026 single intravenous infusion groups and 16 healthy subjects were enrolled in JS026-JS016 groups.JS026 was sequentially administered from low dose to high dose(30-1 000 mg),with intravenous infusion of JS026 or placebo in JS026 single-dose groups,and intravenous infusion of JS026-JS016 or placebo in the combination drug groups.Blood was collected according to the time point designed for trial.Serum concentrations of JS026 and JS016 were determined by enzyme linked immunosorbnent assay(ELISA),and pharmacokinetics parameters were calculated by WinNonlin 8.2.The power model method was used to evaluate the linear analysis of dose and drug exposure.Results 47 subjects completed trial and 1 subject lost to follow-up.After a single intravenous injection of JS026 of 30 mg,100 mg,300 mg,600 mg,and 1 000 mg,mean Cmax were(9.47±1.53),(33.20±4.95),(96.10±13.70),(177.00±22.20)and(353.00±56.70)μg·mL-1,respectively;mean AUC0-∞ were(4 225.00±607.00),(1.78 × 104±3 268.00),(5.83 × 104±1 038.00),(1.07 × 105±152.00),(1.66 × 105±327.00)μg·h·mL-1,respectively;mean t1/2 of JS026 were 563-709 h.The Cmax and AUC0-∞ of JS026 were basically similar alone or in combination with JS016.The results of Power model showed that Cmax and AUC0-∞ increased approximately linearly with the increasing dose of JS026.Treatment emergent adverse event was not increasing when dose increased and most of adverse event associated with drugs were abnormal on laboratory tests and haematuria,thus JS026 and JS016 was well tolerated in all groups.Conclusion The single intravenous infusion of JS026 can almost be thought to be a linear relationship between the doses and drug serum exposure.JS016 had no significant effect on serum concentration of JS026 and JS026 was well tolerated and safe in healthy subjects within 30-1 000 mg.
7.Synthesis and biological activity evaluation of phthalimide-donepezil hybrids
Jun-jie WANG ; Ye-shu MU ; Chen HONG ; Wen LUO
Acta Pharmaceutica Sinica 2024;59(3):651-660
A series of phthalimide-donepezil (PTA-DPZ) hybrids (
8.Clinical guidelines for the treatment of ankylosing spondylitis combined with lower cervical fracture in adults (version 2024)
Qingde WANG ; Yuan HE ; Bohua CHEN ; Tongwei CHU ; Jinpeng DU ; Jian DONG ; Haoyu FENG ; Shunwu FAN ; Shiqing FENG ; Yanzheng GAO ; Zhong GUAN ; Hua GUO ; Yong HAI ; Lijun HE ; Dianming JIANG ; Jianyuan JIANG ; Bin LIN ; Bin LIU ; Baoge LIU ; Chunde LI ; Fang LI ; Feng LI ; Guohua LYU ; Li LI ; Qi LIAO ; Weishi LI ; Xiaoguang LIU ; Hongjian LIU ; Yong LIU ; Zhongjun LIU ; Shibao LU ; Yong QIU ; Limin RONG ; Yong SHEN ; Huiyong SHEN ; Jun SHU ; Yueming SONG ; Tiansheng SUN ; Yan WANG ; Zhe WANG ; Zheng WANG ; Hong XIA ; Guoyong YIN ; Jinglong YAN ; Wen YUAN ; Zhaoming YE ; Jie ZHAO ; Jianguo ZHANG ; Yue ZHU ; Yingjie ZHOU ; Zhongmin ZHANG ; Wei MEI ; Dingjun HAO ; Baorong HE
Chinese Journal of Trauma 2024;40(2):97-106
Ankylosing spondylitis (AS) combined with lower cervical fracture is often categorized into unstable fracture, with a high incidence of neurological injury and a high rate of disability and morbidity. As factors such as shoulder occlusion may affect the accuracy of X-ray imaging diagnosis, it is often easily misdiagnosed at the primary diagnosis. Non-operative treatment has complications such as bone nonunion and the possibility of secondary neurological damage, while the timing, access and choice of surgical treatment are still controversial. Currently, there are no clinical practice guidelines for the treatment of AS combined with lower cervical fracture with or without dislocation. To this end, the Spinal Trauma Group of Orthopedics Branch of Chinese Medical Doctor Association organized experts to formulate Clinical guidelines for the treatment of ankylosing spondylitis combined with lower cervical fracture in adults ( version 2024) in accordance with the principles of evidence-based medicine, scientificity and practicality, in which 11 recommendations were put forward in terms of the diagnosis, imaging evaluation, typing and treatment, etc, to provide guidance for the diagnosis and treatment of AS combined with lower cervical fracture.
9.Non-structural maintenance of chromosome condensin Ⅰ complex subunit G promoting the proliferation,migration and invasion of ovarian cancer cells by the Akt signaling pathway
Ming-Shu ZHANG ; Yi-Hui WANG ; Qing ZHANG ; Li-Ping YE
Acta Anatomica Sinica 2024;55(5):573-581
Objective To explore the regulatory mechanism of non-structural maintenance of chromosome condensin Ⅰ complex submit G(NCAPG)on proliferation,migration,and invasion of ovarian cancer cells.Methods The bioinformatics database was used to analyze the differential expression of NCAPG in ovarian cancer tissues.Western blotting was used to detect the protein expression of NCAPG in normal ovarian epithelial cells IOSE80,ovarian cancer A2780 and SKOV3 cells.The silencing experiments of NCAPG siRNA were divided into blank,control,siNCAPG-1 and siNCAPG-2 groups.The overexpression experiments of NCAPG plasmid were divided into blank,control,NCAPG,NCAPG+MK2206 and MK2206 groups.MTT assay was used to detect cell proliferation activity.Cell scoring assay and transwell assay were used to analyze cell migration and invasion.The protein expressions of p-Akt,total(t)-Akt,proliferative cellular nucleus antigen(PCNA),matrix metallopeptidase 9(MMP-9),vimentin,N-cadherin,and E-cadherin were detected by Western blotting.Results NCAPG was highly expressed in ovarian cancer tissues and cells.Knockdown of NCAPG significantly inhibited the proliferation,invasion and migration of ovarian cancer SKOV3 cells.The protein expressions of p-Akt,PCNA,MMP-9,vimentin and N-cadherin decreased while E-cadherin expression increased.Overexpression of NCAPG significantly promoted the proliferation,invasion and migration of ovarian cancer A2780 cells.The protein expressions of p-Akt,PCNA,MMP-9,vimentin,and N-cadherin increased while E-cadherin expression decreased.Akt inhibitor MK2206 significantly attenuated the above effects of NCAPG.Conclusion NCAPG promotes the proliferation,invasion,and migration of ovarian cancer cells by activating the Akt signaling pathway and regulating the expression of PCNA,MMP-9,and epithelial-mesenchymal transition(EMT)-related proteins.
10.Efficacy and safety of oral sodium sulfate solution for bowel preparation before colonoscopy: a phase Ⅲ multi-center randomized controlled trial
Yanhua ZHOU ; Ye ZONG ; Shu PANG ; Le XU ; Zhenyu ZHANG ; Mei WANG ; Yongdong WU
Chinese Journal of Digestive Endoscopy 2024;41(5):359-365
Objective:To evaluate the efficacy and safety of oral sulfate solution (OSS) for bowel preparation.Methods:A multi-center, randomized, single-blinded, positive-controlled and non-inferiority clinical study was conducted. Participants were randomized to receive two bottles of OSS or 4-liter polyethylene glycol (Ⅲ) (PEG) regimen. The primary indicator was efficacy for bowel preparation. Boston bowel preparation scale (BBPS) ≥2 scores in each segment was determined as effective. Secondary endpoints included subjects' compliance, colonoscopy bubble evaluation, time interval of defecation after medication, time interval of defecation type Ⅶ (Bristol stool classification), the number of defecation, and the positive rate of colonoscopy (detection rate of polyps, non-polyp eminence, ulcers, etc.) were also recorded. The safety was evaluated by the incidence of adverse events and severe adverse events.Results:A total of 240 subjects from 4 hospitals were enrolled in the study, with 120 subjects in the experimental group (the OSS group) and 120 subjects in the control group (the PEG group). The full analysis set (FAS) showed that the bowel preparation success rates were 92.44% (110/119) in the OSS group and 91.60% (109/119) in the PEG group ( χ2=0.058, P=0.809) . The total BBPS score and the scores of each bowel segment were all higher in the OSS group than those in the PEG group ( P<0.05) in both FAS and per protocol set (PPS) except the score of left colon in the FAS. The satisfaction rate of bubble evaluation in the OSS group was higher ( 95.80% VS 89.08%, P=0.025). The compliance, positive rate of colonoscopy and safety of the two groups were comparable. Conclusion:Compared with 4-liter PEG regimen, OSS regimen shows similar bowel preparation quality, superior anti-foaming effect with acceptable safety.

Result Analysis
Print
Save
E-mail